Abnormal angiogenesis in diabetes mellitus
暂无分享,去创建一个
[1] M. Cotter,et al. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats , 2004, Diabetologia.
[2] T. Hostetter. Prevention of end-stage renal disease due to type 2 diabetes. , 2001, The New England journal of medicine.
[3] J. Garb,et al. Basic fibroblast growth factor stimulates angiogenesis in the hindlimb of hyperglycemic rats. , 1998, The Journal of surgical research.
[4] J. Waltenberger,et al. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. , 2000, Circulation.
[5] P. Thuluvath,et al. Outcome of liver transplantation in patients with diabetes mellitus: A case‐control study , 2001 .
[6] S. Nussey,et al. Synthesis of NG, NG Dimethylarginine by Human Endothelial Cells , 1993 .
[7] M. Haneda,et al. Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] A. Abacı,et al. Effect of diabetes mellitus on formation of coronary collateral vessels. , 1999, Circulation.
[9] M. Cotter,et al. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic ratsand nerve function , 1993, Diabetologia.
[10] D. Cheresh,et al. Cell adhesion and angiogenesis. , 1996, Trends in cell biology.
[11] J. Isner,et al. Therapeutic Angiogenesis for Coronary Artery Disease , 2002, Annals of Internal Medicine.
[12] D. Stewart,et al. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. , 1998, Circulation research.
[13] M. Cotter,et al. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. , 1995, The Journal of clinical investigation.
[14] K. Sharma,et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[15] L. Rand. Recent advances in diabetic retinopathy. , 1981, The American journal of medicine.
[16] P. Sloan,et al. The effect of streptozotocin-induced experimental diabetes mellitus on calvarial defect healing and bone turnover in the rat. , 2001, International journal of oral and maxillofacial surgery.
[17] G. Schatteman,et al. Angiogenesis: New insights and therapeutic potential , 2000, The Anatomical record.
[18] M. Longaker,et al. Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes. , 1995, The Journal of Biological Chemistry.
[19] J. Tooke,et al. Aetiology of Diabetic Foot Ulceration: A Role for the Microcirculation? , 1992, Diabetic medicine : a journal of the British Diabetic Association.
[20] M. Grant,et al. Neovascular growth factors , 1991, Eye.
[21] M. Roberts,et al. Distribution of systemically administered ampicillin, benzylpenicillin, and flucloxacillin in excisional wounds in diabetic and normal rats and effects of local topical vasodilator treatment , 1996, Antimicrobial agents and chemotherapy.
[22] E S Gragoudas,et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. , 1996, Ophthalmology.
[23] S. Bonner-Weir,et al. Beneficial Influence of Glycemic Control Upon the Growth and Function of Transplanted Islets , 1994, Diabetes.
[24] S. Bonner-Weir,et al. Vulnerability of Islets in the Immediate Posttransplantation Period: Dynamic Changes in Structure and Function , 1996, Diabetes.
[25] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[26] A. Balamurugan,et al. Successful Subcutaneous Pancreatic Islet Transplantation Using an Angiogenic Growth Factor–Releasing Device , 2001, Pancreas.
[27] C. Dafogianni,et al. Serum Angiogenin Levels in Children and Adolescents with Insulin-Dependent Diabetes Mellitus , 1998, Pediatric Research.
[28] E. Reece,et al. Multifactorial basis of the syndrome of diabetic embryopathy. , 1996, Teratology.
[29] J. Mestan,et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. , 1999, Pharmacology & therapeutics.
[30] S. Kagami,et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. , 1994, The Journal of clinical investigation.
[31] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[32] S. Bursell,et al. Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor , 1996, Science.
[33] Z. Makita,et al. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy , 1991, The Journal of experimental medicine.
[34] M. Serio,et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. , 1999, Journal of the American Society of Nephrology : JASN.
[35] R. Frank. Vascular endothelial growth factor--its role in retinal vascular proliferation. , 1994, The New England journal of medicine.
[36] A. Rose,et al. Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material , 1992, The Journal of pathology.
[37] M. Bitar,et al. Transforming growth factor-beta and insulin-like growth factor-I in relation to diabetes-induced impairment of wound healing. , 1996, The Journal of surgical research.
[38] A. Barden,et al. Advanced Glycation End Products: A Review , 2013 .
[39] J P Cooke,et al. The Pathophysiology of Peripheral Arterial Disease: Rational Targets for Drug Intervention , 1997, Vascular medicine.
[40] K. Suzuma,et al. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. , 2000, Investigative ophthalmology & visual science.
[41] J. Ware,et al. Inhibition of Protein Kinase C&agr; Prevents Endothelial Cell Migration and Vascular Tube Formation In Vitro and Myocardial Neovascularization In Vivo , 2002, Circulation research.
[42] S. Moncada,et al. Endogenous Dimethylarginine as an Inhibitor of Nitric Oxide Synthesis , 1992, Journal of cardiovascular pharmacology.
[43] B. Avcı,et al. Serum 1,25 dihydroxy vitamin D (1,25(OH)2D3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. , 2000, Clinical biochemistry.
[44] D. Greene,et al. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. , 2000, Diabetes.
[45] J. Eng,et al. Increased basic fibroblast growth factor-like substance in plasma from a subset of middle-aged or elderly male diabetic patients with microalbuminuria or proteinuria. , 1996, The Journal of clinical endocrinology and metabolism.
[46] K. Alitalo,et al. Vascularization of the mouse embryo: A study of flk‐1, tek, tie, and vascular endothelial growth factor expression during development , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.
[47] I. Buschmann,et al. Collateral circulation and diabetes. , 1999, Circulation.
[48] K Messmer,et al. Angiogenesis and Hemodynamics of Microvasculature of Transplanted Islets of Langerhans , 1989, Diabetes.
[49] J. Ronan,et al. Acidic fibroblast growth factor accelerates dermal wound healing in diabetic mice. , 1995, The Journal of investigative dermatology.
[50] M. Blagosklonny,et al. UCN-01, a Protein Kinase C Inhibitor, Inhibits Endothelial Cell Proliferation and Angiogenic Hypoxic Response , 1998, Invasion and Metastasis.
[51] J. Nyengaard,et al. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes , 1993, Diabetologia.
[52] L. Aiello,et al. Role of vascular endothelial growth factor in diabetic vascular complications. , 2000, Kidney international. Supplement.
[53] P. Cryer,et al. Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus. , 1982, The Journal of clinical investigation.
[54] Y. Mori,et al. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. , 2001, Circulation research.
[55] A. Griffioen,et al. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.
[56] J. Cheigh,et al. Kidney Transplantation in Patients with Type 1 Diabetes Mellitus: Long-Term Prognosis for Patients and Grafts , 2001, The Korean journal of internal medicine.
[57] G. Lip,et al. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. , 2000, Investigative ophthalmology & visual science.
[58] P Lavie,et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. , 1999, Circulation.
[59] M. Caliari,et al. Aminoguanidine Prevents Impaired Healing and Deficient Angiogenesis in Diabetic Rats , 1999, Inflammation.
[60] K. Takeuchi,et al. Impaired healing of gastric lesions in streptozotocin-induced diabetic rats: effect of basic fibroblast growth factor. , 1997, The Journal of pharmacology and experimental therapeutics.
[61] J. Isner,et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. , 1997, Circulation.
[62] E. Manseau,et al. Vascular permeability factor mRNA and protein expression in human kidney. , 1992, Kidney international.
[63] B. Spiegelman,et al. Vasodilation of rat retinal microvessels induced by monobutyrin. Dysregulation in diabetes. , 1993, The Journal of clinical investigation.
[64] G. Kouvaras,et al. Comparison of coronary collateral circulation in diabetic and nondiabetic patients suffering from coronary artery disease , 1999, Clinical cardiology.
[65] B. Brenner,et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.
[66] R. Tilton,et al. Antibodies against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experimental Diabetes Materials and Methods Laboratory Animals , 2022 .
[67] A. Sommer,et al. Recombinant basic fibroblast growth factor accelerates wound healing. , 1988, The Journal of surgical research.
[68] M Linet,et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. , 1997, Journal of the National Cancer Institute.
[69] G. Lutty,et al. Localization of vascular endothelial growth factor in human retina and choroid. , 1996, Archives of ophthalmology.
[70] S. Bode-Böger,et al. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. , 1996, Biochemical and biophysical research communications.
[71] R. McCarter,et al. Maternal diabetes and cardiovascular malformations: predominance of double outlet right ventricle and truncus arteriosus. , 1990, Teratology.
[72] R. Kronmal,et al. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged > or = 65 years (report from the Coronary Artery Surgery Study [CASS] Registry). , 1994, The American journal of cardiology.
[73] S. P. Andrade,et al. Glucose-induced inhibition of angiogenesis in the rat sponge granuloma is prevented by aminoguanidine. , 1999, Life sciences.
[74] G. Wu,et al. Arginine nutrition and cardiovascular function. , 2000, The Journal of nutrition.
[75] M. Cooper,et al. Vascular changes in the diabetic kidney: effects of ACE inhibition. , 1995, Journal of diabetes and its complications.
[76] K. Blennow,et al. The Role of the Polymorphic Genes Apolipoprotein E and Methylene- tetrahydrofolate Reductase in the Development of Dementia of the Alzheimer Type , 1999, Dementia and Geriatric Cognitive Disorders.
[77] J. Waltenberger. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. , 2001, Cardiovascular research.
[78] Liying Sun,et al. Transfection with aFGF cDNA improves wound healing. , 1997, The Journal of investigative dermatology.
[79] M. Grant,et al. Fibronectin Fragments Modulate Human Retinal Capillary Cell Proliferation and Migration , 1998, Diabetes.
[80] M. Nattrass,et al. Insulin Resistance: a Multifaceted Metabolic Syndrome. Insights Gained Using a Low‐dose Insulin Infusion Technique , 1996, Diabetic medicine : a journal of the British Diabetic Association.
[81] I. Hirsch,et al. Higher Glycemic Thresholds for Symptoms During β-Adrenergic Blockade in IDDM , 1991, Diabetes.
[82] A. Patz. Clinical and experimental studies on retinal neovascularization. XXXIX Edward Jackson Memorial Lecture. , 1982, American journal of ophthalmology.
[83] D. Loskutoff,et al. Tissue factor gene expression in the adipose tissues of obese mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[84] H. Gröne,et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. , 1998, Journal of the American Society of Nephrology : JASN.
[85] Y. Marcel,et al. Apolipoprotein A-I Conformation in Reconstituted Discoidal Lipoproteins Varying in Phospholipid and Cholesterol Content (*) , 1995, The Journal of Biological Chemistry.
[86] Yukitaka Shizukuda,et al. Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cdelta activity. , 1999, Circulation research.
[87] P. Reitz,et al. Effects of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, TGF-α, TGF-β, bFGF and Vimentin) in cultured and transplanted rat islets , 2000, Diabetologia.
[88] J. R. Mekkes,et al. Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation , 1999, Archives of Dermatological Research.
[89] Y. Kaneda,et al. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. , 1996, Kidney international.
[90] G. Jerums,et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes , 2000, Diabetologia.
[91] S. Homma,et al. Acute Elevations of Plasma Asymmetric Dimethylarginine and Impaired Endothelial Function in Response to a High-Fat Meal in Patients With Type 2 Diabetes , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[92] J. Cooke,et al. Does ADMA cause endothelial dysfunction? , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[93] E. Middelkoop,et al. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. , 1998, The Journal of investigative dermatology.
[94] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[95] S. Moncada,et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.
[96] D. Cucinotta,et al. Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. , 2001, Diabetes.
[97] B. Williams. A Potential Role for Angiotensin II-Induced Vascular Endothelial Growth Factor Expression in the Pathogenesis of Diabetic Nephropathy? , 1998, Mineral and Electrolyte Metabolism.
[98] C. Kilo,et al. Diabetes-induced increases in vascular permeability and changes in granulation tissue levels of sorbitol, myo-inositol, chiro-inositol, and scyllo-inositol are prevented by sorbinil. , 1986, Metabolism: clinical and experimental.
[99] J. Cooke,et al. Angiogenesis Is Impaired by Hypercholesterolemia: Role of Asymmetric Dimethylarginine , 2000, Circulation.
[100] M. Dewhirst,et al. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. , 1997, Circulation research.
[101] H. Hammes,et al. Integrin Chatter and Vascular Function in Diabetic Retinopathy , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[102] R. Natarajan,et al. A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. , 1996, The Journal of clinical endocrinology and metabolism.
[103] D. Cockroft,et al. Teratogenic effects of excess glucose on head-fold rat embryos in culture. , 1977, Teratology.
[104] L. Baker,et al. Diabetic embryopathy: a selective review of recent trends. , 1993, Journal of diabetes and its complications.
[105] B. Spiegelman. PPARγ in Monocytes: Less Pain, Any Gain? , 1998, Cell.
[106] E. Van Obberghen,et al. Regulation of Vascular Endothelial Growth Factor Expression by Advanced Glycation End Products* , 2001, The Journal of Biological Chemistry.
[107] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[108] G. Wolf,et al. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. , 1992, The American journal of pathology.
[109] M. Cooper,et al. Role of Endothelium-Derived Nitric Oxide in the Pathogenesis of the Renal Hemodynamic Changes of Experimental Diabetes , 1994, Diabetes.
[110] O. Carpén,et al. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. , 2001, Molecular human reproduction.
[111] J. Isner,et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. , 1999, The American journal of pathology.
[112] L. Aiello,et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. , 1996, The Journal of clinical investigation.
[113] D. Charnock-Jones,et al. Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. , 1996, Human reproduction.
[114] M. Cotter,et al. Effects of the diacylglycerol complexing agent, cremophor, on nerve-conduction velocity and perfusion in diabetic rats. , 1999, Journal of diabetes and its complications.
[115] Y. Wang,et al. Hyperglycemia-induced vasculopathy in the murine vitelline vasculature: correlation with PECAM-1/CD31 tyrosine phosphorylation state. , 1999, The American journal of pathology.
[116] R. Zatz,et al. Renal effects of acute and chronic nitric oxide inhibition in experimental diabetes. , 1996, Nephron.
[117] Peipei Ping,et al. Intracoronary gene transfer of fibroblast growth factor–5 increases blood flow and contractile function in an ischemic region of the heart , 1996, Nature Medicine.
[118] J. Styrud,et al. Diabetic Embryopathy Studies With Animal and In Vitro Models , 1991, Diabetes.
[119] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[120] B. Gallacher,et al. Glucose-Induced Protein Kinase C Activation Regulates Vascular Permeability Factor mRNA Expression and Peptide Production by Human Vascular Smooth Muscle Cells In Vitro , 1997, Diabetes.
[121] C. Léránth,et al. Yolk sac failure in embryopathy due to hyperglycemia: ultrastructural analysis of yolk sac differentiation associated with embryopathy in rat conceptuses under hyperglycemic conditions. , 1986, Teratology.
[122] P. Tsao,et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. , 1998, Circulation.
[123] D. Harrison,et al. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[124] A. Hartner,et al. J Am Soc Nephrol 11: 71–79, 2000 Nitric Oxide Synthase Isoforms and Glomerular Hyperfiltration in Early Diabetic Nephropathy , 2022 .
[125] J. Pfeilschifter,et al. Expressional Regulation of Angiopoietin-1 and -2 and the Tie-1 and -2 Receptor Tyrosine Kinases during Cutaneous Wound Healing: A Comparative Study of Normal and Impaired Repair , 2001, Laboratory Investigation.
[126] J. Williamson,et al. Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. , 2001 .
[127] Z. Makita,et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 , 1999, Diabetologia.
[128] C. Kilo,et al. Sorbinil Prevents Diabetes-induced Increases in Vascular Permeability But Does Not Alter Collagen Cross-Linking , 1985, Diabetes.
[129] A. Joly,et al. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. , 2001, Endocrinology.
[130] L. Gnudi,et al. Interaction of Angiotensin Ii and Mechanical Stretch on Vascular Endothelial Growth Factor Production by Human Mesangial Cells , 2022 .
[131] G. Steil,et al. GENE EXPRESSION OF VEGF AND ITS RECEPTORS Flk-1/KDR AND Flt-1 IN CULTURED AND TRANSPLANTED RAT ISLETS1 , 2001, Transplantation.
[132] O. Korsgren,et al. Effects of Hyperglycemia on Function of Isolated Mouse Pancreatic Islets Transplanted Under Kidney Capsule , 1989, Diabetes.
[133] D. Birnbaum,et al. Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively. , 1996, Genomics.
[134] K. Sharma,et al. Hyperglycemia and Diabetic Kidney Disease: The Case for Transforming Growth Factor–β as a Key Mediator , 1995, Diabetes.
[135] G. Garcı́a-Cardeña,et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.
[136] Timothy McCaffrey,et al. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation , 2001, Nature Medicine.
[137] K. Preissner,et al. Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy. , 1995, Experimental eye research.
[138] M. Cooper,et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. , 1999, Diabetes.
[139] D. Cucinotta,et al. Raxofelast, a hydrophilic vitamin E-like antioxidant, stimulates wound healing in genetically diabetic mice. , 2001, Surgery.
[140] H. Itoh,et al. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. , 1993, The Journal of clinical investigation.
[141] G. King,et al. Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. , 1997, Journal of the American Society of Nephrology : JASN.
[142] D. C. Han,et al. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. , 2000, American journal of physiology. Renal physiology.
[143] M. Cotter,et al. Essential Fatty Acid Diet Supplementation: Effects on Peripheral Nerve and Skeletal Muscle Function and Capillarization in Streptozocin-Induced Diabetic Rats , 1991, Diabetes.